We report the radiosynthesis and evaluation of 
3-[3,5-dimethyl-4-(4-[11C]methylpiperazinecarbonyl)-1H-pyrrol-2-ylmethylene]-2-oxo-2,3-dihydro-1H-indole-5-sulfonic 
acid (3-chlorophenyl)methylamide, termed [11C]SU11274 ([11C]14) for in vivo 
imaging of mesenchymal-epithelial transition (MET) receptor by positron emission 
tomography (PET). Following the synthesis of the precursor (13) that was 
achieved in 10 steps with a total yield of 9.7%, [11C]14 was obtained through 
radiomethylation in a range of 5-10% radiochemical yield and over 95% 
radiochemical purity. For in vivo PET studies, two human lung cancer xenograft 
models were established using MET-positive NCI-H1975 and MET-negative NCI-H520 
cell lines. Quantitative [11C]14-PET studies showed that the tumor uptake of 
[11C]14 in the NCI-H1975 xenografts was significantly higher than that in the 
NCI-H520 xenografts, which is consistent with their corresponding 
immunohistochemical tissue staining patterns of MET receptors from the same 
animals. These studies demonstrated that [11C]14-PET is an appropriate imaging 
marker for quantification of MET receptor in vivo, which can facilitate efficacy 
evaluation in the clinical development of MET-targeted cancer therapeutics.